Novavax Booster con adyuvante se adapta a las nuevas variantes24 de octubre de 2022Nina CosdónConferencia | Semana de identificación¿Qué hace que el refuerzo COVID-19 de Novavax sea diferente? La vacuna adyuvada “ha seguido reconociendo las variantes que se presentan”, dice el director ejecutivo de Novavax, Germán Áñez, MD.La semana pasada, la vacuna COVID-19 con adyuvante de Novavax fue autorizada como la inyección de refuerzo heteróloga más nueva en los EE. UU.Play VideoEl booster de Novavax , NVX-CoV2373, fue autorizado previamente en otras geografías, incluso en la Unión Europea . En los EE. UU., será la tercera dosis de refuerzo de COVID-19, junto con Pfizer-BioNTech y Moderna, disponible después de una serie de vacunas primarias.En la conferencia IDWeek , nos sentamos con el director ejecutivo de Desarrollo Clínico de Novavax, Germán Áñez, MD, para obtener más información sobre esta nueva vacuna de refuerzo sin ARNm.Un mes después de recibir la vacuna de refuerzo Novavax, dijo Añéz, los participantes del ensayo tenían títulos de anticuerpos neutralizantes y títulos de IgG de unión que eran aproximadamente 3 veces más altos que después de la vacunación primaria. Esto cumplió con los criterios de no inferioridad.Añéz dijo que estos resultados se esperaban en gran medida, pero un resultado sorprendente fue lo bien que se desempeñó el refuerzo contra las subvariantes de Omicron. “Probamos muestras contra 3 sabores diferentes de la variante de Omicron, BA.1, BA.2 y BA.5”, dijo, y enfatizó que encontraron títulos altos a pesar de que la vacuna de refuerzo no contiene una secuencia de Omicron.“Esos títulos fueron tan altos como los títulos observados después de la vacunación primaria contra Wuhan, y eso se correlaciona con una eficacia de más del 90 %”. Añéz dijo que estos resultados se mantuvieron consistentes en variables como el tiempo después de la vacunación y la edad de los participantes.La tecnología adyuvante de NVX-CoV2373 “está permitiendo que la vacuna funcione como lo está haciendo ahora, lo que significa que ha seguido reconociendo las variantes que surgen”, explicó Añéz.“El adyuvante es responsable de estas fuertes respuestas humorales que hemos observado hasta ahora frente a todas las variantes que hemos probado”.Contenido relacionado:Videos CORONAVIRUS COVID VACUNA RAZA VACUNAS ConferenciasConstruyendo impulso para la Ley PasteurDescripción general del virus SARS-CoV-2 y sus subvariantes¿Quién no ama una precuela? SARS antes del CoV-2Construyendo impulso para la Ley Pasteur24 de octubre de 2022juan parkinsonConferencia | Semana de identificaciónUn miembro del liderazgo de la Sociedad de Enfermedades Infecciosas de América (IDSA) siente que se están logrando algunos avances en el Congreso para esta legislación de resistencia a los antimicrobianos.Play VideoTo the general public and those outside the Washington DC beltway, the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act seems like it is stalled and might not have a chance to get passed.Initially introduced in Congress by US Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) in September of 2020, Bennet and Young along with and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) reintroduced the bill in June 2021.For the uninitiated, the Pasteur Act is a bipartisan, bicameral piece of legislation aimed to incentivize innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics, and ensure domestic availability when needed.As the prospective legislation was drafted over two years ago, it seems as if the bill has languished in getting through Congress.However, to Amanda Jezek, senior vice president of public policy and government relations at IDSA, she has a different perspective.“We are fighting to make sure we have a much stronger antibiotic arsenal because we don’t want any single physician to tell their patient I’m sorry we are out of options,” Jezek said in an interview at ID Week.She is optimistic that the legislation will be passed. She said there are 65 bipartisan cosponsors in Congress for the bill. As part of trying to emphasize the bill, members of the IDSA Board members who were in Washington this past week visited with Health and Human Services (HHS) Secretary Xavier Becerra as well as different members of Congress. When talking to staff of republican and democratic congressional members there is a bipartisan appeal to the Pasteur Act according to Jezek.“Everywhere we go, people say, ‘yes we need action on AMR,’” Jezek stated. “We are excited to keep building the momentum and get this bill across the finish line and send it to the President’s desk.”Jezek sat down to talk with Contagion who offered some insights into what IDSA is doing in terms of advocacy overall as well as with the Pasteur Act.Related Content:VideosConferencesWho Doesn’t Love a Prequel? SARS Before CoV-2Reevaluating Susceptibility BreakpointsTreating Expecting Mothers With Sotrovimab for COVID-19Overview of SARS-CoV-2 Virus and SubvariantsOctober 24, 2022Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc , Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, Jacinda C. Abdul-Mutakabbir, PharmD, MPH, AAHIVP, Madeline King, PharmD, BCIDPJacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.Play VideoRodney Rohde, SV, SM, MB (ASCP), FACSc: Hello, and welcome to this Peer Exchange titled “Recent Approvals in Vaccination Against SARS-CoV-2 and the Omicron Subvariants”. My name is Dr Rodney E. Rohde. I’m a regents professor, a research dean, and the chair of the clinical laboratory science program at Texas State University in the College of Health Professions in San Marcos, Texas. It’s my honor to join you guys. Joining me are my colleagues, and I’ll let each of them introduce themselves.Jacinda Abdul-Mutakabbir, PharmD: Hi, everyone. My name is Dr Jacinda Abdul-Mutakabbir, but I go by Dr JAM or JAM. I’m an assistant professor at Loma Linda University in Loma Linda, California.Madeline King, PharmD, BCIDP: Hi, my name is Dr Madeline King. I’m an infectious disease clinical pharmacist, and I practice as an outpatient infectious disease pharmacist at Cooper University Hospital in Camden, New Jersey.Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP: Hi, everyone. I’m Dr Wendy Wright, an adult and family nurse practitioner, and the owner of 2 nurse practitioner owned and operated primary care clinics in New Hampshire. It’s truly my pleasure to be with all of you.Rodney Rohde, SV, SM, MB (ASCP), FACSc: It’s great to meet everyone and hear your backgrounds. Our discussion will be focused on providing an overview of some of the recently approved SARS-CoV-2 booster shots, highlighting some of the recommendations and how to discuss these vaccination options with patients. Welcome, everyone. Let’s get started.In our first segment we’ll talk about a general overview around SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] and the variants involved in that outbreak and pandemic. Dr JAM, I’ll start with you. Would you like to discuss the difference between the original SARS-CoV-2 strain, which was discovered about 2½ years ago, and the subsequent subvariants that have been percolating through society since that time?Jacinda Abdul-Mutakabbir, PharmD: Thank you for that question, Rodney. It’s one I get often. When we think about the differences between the original COVID-19 strain, or what we in the community call the OG strain, and then compare that with the subvariants that we see, it’s just a matter of genetic mutations that multiply and then cause these subvariants to be prevalent.Then I come into this place of asking, how are these subvariants identified? How is it that we named them? And so on and so forth. This was a learning moment for me. We use the Phylogenetic Assignment of Named Global Outbreak Lineages, or the PANGOLIN nomenclature. That’s how we end up with B.1,B.5, and so on. Then the World Health Organization designates specific names to the variant. At this point, we’re 15 letters into the Greek alphabet at Omicron. They started with Alpha. Those are the differences we see in terms of our original COVID-19 strain and the subvariants that we’re seeing.Rodney Rohde, SV, SM, MB (ASCP), FACSc: Thanks for that explanation. As a virologist, I’m often answering those questions as well. As many of you know, a lot of these viruses sometimes get named from their origin. We’ve tried to stop doing that so that we can quit placing a geographic location or some other nomenclature that might be looked upon as a stigma. That’s the reasoning behind some of that. Thank you, Dr JAM, for that information.Transcript Edited for ClarityRelated Content:Recent Approvals in Vaccination Against SARS-CoV-2 and the Omicron SubvariantsPeer ExchangeCOVID VACCINE RACEReevaluating Susceptibility BreakpointsTreating Expecting Mothers With Sotrovimab for COVID-19Investigational RSV Vaccine for Seniors Demonstrates Efficacy and Safety
